clinical trial · NCT06095505
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Small Cell Lung CancerAlisertib
brief summary
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1 immunotherapy agent. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior lines of therapy. This study is intended to identify the biomarker-defined subgroup(s) that may benefit most from alisertib treatment and to evaluate the efficacy, safety, and pharmacokinetics of alisertib.
started
Feb 8, 2024
primary completion
Apr 30, 2027
completion
Oct 31, 2027
last updated
Feb 17, 2026
official title
A Phase 2 Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol